+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are observing the effects of darolutamide combined with androgen deprivation therapy ADT in men with non-metastatic castration-resistant prostate cancer nmCRPC in China. These men previously received bicalutamide plus ADT for non-metastatic hormone-sensitive prostate cancer nmHSPC but their cancer progressed despite treatment. Prostate cancer is common and often diagnosed late in China, making new treatments important. Darolutamide has shown promise in controlling cancer progression with fewer severe side effects compared to older therapies. Participants in this observational study receive darolutamide and ADT according to local standard care practices. The study includes a main group of 800 men followed for 6 months and a smaller group of 100 men observed for 12 months. The study does not assign treatments but observes men treated with darolutamide and ADT after progression from prior therapy. Researchers will track prostate-specific antigen PSA levels and other health measures during this time. During the study, participants will have regular assessments to measure PSA levels, which help indicate cancer activity, and to monitor for any adverse medical events. The main outcome is how many men achieve undetectable PSA levels within 6 months, while the smaller group will be observed for PSA progression-free survival at 12 months. Safety is also monitored by recording any side effects or medical problems that occur. The total participation lasts up to 12 months depending on the group.

Age: 18Years +MALE
1 location
C

Actively Recruiting

Researchers are establishing a nationwide prospective database of diabetes patients treated at National Metabolic Management Centers MMCs across China. The study aims to explore epidemiology, genetics, biomarkers, risk factors, and prognostic methods related to diabetes and its complications, as well as other metabolic diseases. It also evaluates current care status, treatment strategies, patient costs, and quality of life to support the Healthy China 2030 strategy. Participants receive standard diabetes management at MMCs, which integrate advanced medical equipment and Internet of Things technology to provide a standardized, convenient, and precise model of care. After a comprehensive baseline evaluation, patients are followed with clinical and laboratory visits every 3 to 6 months based on individualized treatment plans, with yearly comprehensive assessments for glycemic control, risk factors, safety, and diabetes complications. During the study, participants undergo regular clinical and laboratory evaluations including monitoring of blood glucose, blood pressure, lipids, body mass index, and visceral fat. Researchers also assess health-related quality of life, cognitive function, psychological well-being, and cost-effectiveness. The study tracks diabetes-related clinical endpoints such as macrovascular and microvascular morbidity, mortality, infections, heart failure, neuropathy, and cancers, with follow-up lasting up to 20 years.

Age: 18Years +All Genders
1 location
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
H

Actively Recruiting

Healthy Volunteer

Osteopenia is a condition marked by low bone density that can lead to osteoporosis and increased risk of fractures, especially in older women. This research investigates the impact of high-intensity interval training HIIT on bone health and related outcomes in Hong Kong Chinese women aged 60 to 74. The trial aims to address challenges older adults face with traditional exercise programs, such as the need for special equipment and low motivation, by testing a 24-week HIIT program. Participants will be randomly assigned to one of two groups a HIIT exercise group or a non-exercise control group attending recreational workshops. The HIIT program involves twice-weekly sessions over 24 weeks, each lasting 37 to 40 minutes, including warm-up, main exercise with high-impact weight-bearing activities, and cool down. The exercise intensity and complexity progress during the study, with safety measures like chair assistance and added weights in later weeks. Throughout the trial, participants will undergo assessments at three points before the intervention, immediately after 24 weeks, and six months after completion. Measures include bone mineral density, bone turnover markers, physical fitness parameters such as muscle strength and aerobic endurance, fear of falling, and quality of life. This comprehensive evaluation helps researchers understand the effects of HIIT on bone health and overall well-being in older women with osteopenia.

Age: 60Years - 74YearsFEMALEPhase Not Applicable
1 location